Advancis Pharmaceutical Announces Positive Results For Amoxicillin PULSYS Phase III Trial (Medical News Today)
AdvancisPharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focusedon developing and commercializing novel anti-infective products, todayannounced that its Amoxicillin PULSYS Phase III clinical trial for thetreatment of adults and adolescents with pharyngitis/tonsillitis due [click link for full article]

Amarillo Biosciences IND Application Passes FDA Review (SYS-CON Media)
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that the Company's Investigational New Drugapplication (IND) for idiopathic pulmonary fibrosis (IPF) has successfullypassed the FDA's 30-day review process and has been allowed to go intoeffect. A Phase II, 60-patient study to test low dose oral interferon as atreatment of chronic cough in IPF patients is on target to launch in

Introgen Therapeutics Announces Key Regulatory Advance For ADVEXIN Program (Medical News Today)
Introgen Therapeutics,Inc. (Nasdaq: INGN) announced today that the Company and the FDA havereached agreement to incorporate the use of Introgen's biomarkers in theanalysis of ADVEXIN clinical data in support of FDA approval of ADVEXIN p53cancer therapy. [click link for full article]